This Plain Language Summary of Publication article (PLSP) from Expert Review of Hematology investigates inotuzumab ozogamicin (InO), which offers superior efficacy compared to standard chemotherapy for acute lymphoblastic leukemia (ALL), especially for relapsed or refractory cases. Treatment response varies significantly among patients, requiring careful consideration of individual and disease factors when selecting appropriate candidates for InO therapy.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review’ and was published in the Expert Review of Hematology.

Visit Taylor & Francis Online using the link to read the original article.